| [1] |
Haugen BR, Alexander EK, Bible KC, et al.
2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. ThyroidThyroid, 2016, 26(1): 1-133.
doi: 10.1089/thy.2015.0020 |
| [2] |
Sohn SY, Kim HI, Kim YN, et al.
Prognostic indicators of outcomes in patients with lung metastases from differentiated thyroid carcinoma during long-term follow-up[J]. Clin EndocrinolClin Endocrinol, 2018, 88(2): 318-326.
doi: 10.1111/cen.13489 |
| [3] |
Durante C, Haddy N, Baudin E, et al.
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 2006, 91(8): 2892-2899.
doi: 10.1210/jc.2005-2838 |
| [4] |
Hirsch D, Levy S, Tsvetov G, et al.
Long-term outcomes and prognostic factors in patients with differentiated thyroid cancer and distant metastases[J]. Endocr PractEndocr Pract, 2017, 23(10): 1193-1200.
doi: 10.4158/EP171924.OR |
| [5] |
Rehman S, Dhatariya KK. Metastatic hürthle cell carcinoma presenting with low free thyroxine, severe hypercalcemia and spurious growth hormone production[J/OL]. AACE Clin Case Rep, 2019, 5(3): e204−e209[2021-04-26]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876938/. DOI: 10.4158/ACCR-2018-0440. |
| [6] |
李娜, 邸玉青, 高洪波, 等.
儿童分化型甲状腺癌肺转移14例131I治疗分析[J]. 临床儿科杂志临床儿科杂志, 2020, 38(9): 651-654.
doi: 10.3969/j.issn.1000-3606.2020.09.003 Li N, Di YQ, Gao HB, et al. Analysis of 131I therapy of pulmonary metastasis in differentiated thyroid cancer in 14 children[J]. J Clin PediatrJ Clin Pediatr, 2020, 38(9): 651-654. doi: 10.3969/j.issn.1000-3606.2020.09.003 |
| [7] |
Zhao T, Liang J, Li T, et al.
Serial stimulated thyroglobulin measurements are more specific for detecting distant metastatic differentiated thyroid cancer before radioiodine therapy[J]. Chin J Cancer ResChin J Cancer Res, 2017, 29(3): 213-222.
doi: 10.21147/j.issn.1000-9604.2017.03.07 |
| [8] |
李成乾, 王国强, 王叙馥, 等.
首次131I治疗前刺激性Tg对分化型甲状腺癌转移的预测价值[J]. 中华核医学与分子影像杂志中华核医学与分子影像杂志, 2019, 39(7): 395-399.
doi: 10.3760/cma.j.issn.2095-2848.2019.07.003 Li CQ, Wang GQ, Wang XF, et al. Predictive value of stimulated thyroglobulin for metastases from differentiated thyroid carcinoma before the first 131I treatment[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2019, 39(7): 395-399. doi: 10.3760/cma.j.issn.2095-2848.2019.07.003 |
| [9] |
Couto JS, Almeida MFO, Trindade VCG, et al. A cutoff thyroglobulin value suggestive of distant metastases in differentiated thyroid cancer patients[J/OL]. Braz J Med Biol Res, 2020, 53(11): e9781[2021-04-26]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561073/. DOI: 10.1590/1414-431X20209781. |
| [10] |
Ito Y, Onoda N, Kihara M, et al.
Prognostic significance of neutrophil-to-lymphocyte ratio in differentiated thyroid carcinoma having distant metastasis: a comparison with thyroglobulin-doubling rate and tumor volume-doubling rate[J]. In VivoIn Vivo, 2021, 35(2): 1125-1132.
doi: 10.21873/invivo.12358 |
| [11] |
Song HJ, Qiu ZL, Shen CT, et al.
Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors[J]. Eur J EndocrinolEur J Endocrinol, 2015, 173(3): 399-408.
doi: 10.1530/EJE-15-0296 |
| [12] |
Kim M, Kim WG, Park S, et al.
Initial size of metastatic lesions is best prognostic factor in patients with metastatic differentiated thyroid carcinoma confined to the lung[J]. ThyroidThyroid, 2017, 27(1): 49-58.
doi: 10.1089/thy.2016.0347 |
| [13] |
Song EY, Ahn J, Jeon MJ, et al.
Estimating the growth rate of lung metastases in differentiated thyroid carcinoma: response evaluation criteria in solid tumors or doubling time?[J]. ThyroidThyroid, 2020, 30(3): 418-424.
doi: 10.1089/thy.2019.0341 |
| [14] |
李亚, 左书耀, 孔艳, 等.
131I全身显像与CT及X线胸片对分化型甲状腺癌肺转移诊断价值[J]. 齐鲁医学杂志齐鲁医学杂志, 2015, 30(4): 455-456.
doi: 10.13362/j.qlyx.201504026 Li Y, Zuo SY, Kong Y, et al. Diagnostic value of 131I-WBI, CT and chest X-ray for differentiated thyroid cancer with pulmonary metastasis[J]. Med J QiluMed J Qilu, 2015, 30(4): 455-456. doi: 10.13362/j.qlyx.201504026 |
| [15] |
Okuyucu K, Ince S, Alagoz E, et al.
Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging 18F-FDG PET/CT[J]. Hell J Nucl MedHell J Nucl Med, 2016, 19(3): 208-217.
doi: 10.1967/s002449910402 |
| [16] |
Maruoka Y, Baba S, Isoda T, et al.
Association between volumetric analysis of lung metastases on F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography and short-term progression after I-131 therapy for differentiated thyroid carcinoma[J]. Indian J Nucl MedIndian J Nucl Med, 2017, 32(3): 167-172.
doi: 10.4103/ijnm.IJNM_43_17 |
| [17] |
Yang X, Li J, Li XY, et al.
TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer[J]. J Nucl MedJ Nucl Med, 2017, 58(2): 258-265.
doi: 10.2967/jnumed.116.180240 |
| [18] |
Porterfield JR, Cassivi SD, Wigle DA, et al.
Thoracic metastasectomy for thyroid malignancies[J]. Eur J Cardiothorac SurgEur J Cardiothorac Surg, 2009, 36(1): 155-158.
doi: 10.1016/j.ejcts.2008.12.055 |
| [19] |
Moneke I, Kaifi JT, Kloeser R, et al.
Pulmonary metastasectomy for thyroid cancer as salvage therapy for radioactive iodine-refractory metastases[J]. Eur J Cardiothorac SurgEur J Cardiothorac Surg, 2018, 53(3): 625-630.
doi: 10.1093/ejcts/ezx367 |
| [20] |
Verburg FA, Hänscheid H, Luster M.
Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer[J]. Best Pract Res Clin Endocrinol MetabBest Pract Res Clin Endocrinol Metab, 2017, 31(3): 279-290.
doi: 10.1016/j.beem.2017.04.010 |
| [21] |
Chen P, Feng HJ, Ouyang W, et al.
Risk factors for nonremission and progression-free survival after I-131 therapy in patients with lung metastasis from differentiated thyroid cancer: a single-institute, retrospective analysis in southern china[J]. Endocr PractEndocr Pract, 2016, 22(9): 1048-1056.
doi: 10.4158/EP151139.OR |
| [22] |
Gietka-Czernel M, Hubalewska-Dydejczyk A, Kos-Kudła B, et al.
Expert opinion on liquid L-thyroxine usage in hypothyroid patients and new liquid thyroxine formulation-Tirosint SOL [opinia ekspertów dotycząca stosowania płynnej postaci lewotyroksyny oraz nowego preparatu Tirosint SOL u chorych na niedoczynność tarczycy][J]. Endokrynol PolEndokrynol Pol, 2020, 71(5): 441-465.
doi: 10.5603/EP.a2020.0065 |
| [23] |
Carhill AA, Litofsky DR, Ross DS, et al.
Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 2015, 100(9): 3270-3279.
doi: 10.1210/JC.2015-1346 |
| [24] |
Iyengar P, Wardak Z, Gerber DE, et al.
Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial[J]. JAMA OncolJAMA Oncol, 2018, 4(1): e173501-.
doi: 10.1001/jamaoncol.2017.3501 |
| [25] |
Siva S, Macmanus M, Ball D.
Stereotactic radiotherapy for pulmonary oligometastases: a systematic review[J]. J Thorac OncolJ Thorac Oncol, 2010, 5(7): 1091-1099.
doi: 10.1097/JTO.0b013e3181de7143 |
| [26] |
Lee S, Eo W, Jeon H, et al.
Prognostic significance of host-related biomarkers for survival in patients with advanced non-small cell lung cancer[J]. J CancerJ Cancer, 2017, 8(15): 2974-2983.
doi: 10.7150/jca.20866 |
| [27] |
Kim MJ, Kim SM, Lee EK, et al.
Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer[J]. Endocr JEndocr J, 2019, 66(7): 597-604.
doi: 10.1507/endocrj.EJ18-0488 |
| [28] |
Schlumberger M, Tahara M, Wirth LJ, et al.
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J MedN Engl J Med, 2015, 372(7): 621-630.
doi: 10.1056/NEJMoa1406470 |
| [29] |
Lin YS, Wang C, Gao W, et al.
Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer[J]. OncotargetOncotarget, 2017, 8(26): 42252-42261.
doi: 10.18632/oncotarget.15036 |
| [30] |
Sherman SI.
Cytotoxic chemotherapy for differentiated thyroid carcinoma[J]. Clin OncolClin Oncol, 2010, 22(6): 464-468.
doi: 10.1016/j.clon.2010.03.014 |
| [31] |
Spano JP, Vano Y, Vignot S, et al.
GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma[J]. Med OncolMed Oncol, 2012, 29(3): 1421-1428.
doi: 10.1007/s12032-011-0070-2 |
| [32] |
Mould RC, Van Vloten JP, Auyeung AWK, et al.
Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission[J]. Endocr Relat CancerEndocr Relat Cancer, 2017, 24(12): T311-T329.
doi: 10.1530/erc-17-0316 |
| [33] |
Kim JH, Baek JH, Lim HK, et al.
2017 thyroid radiofrequency ablation guideline: Korean society of thyroid radiology[J]. Korean J RadiolKorean J Radiol, 2018, 19(4): 632-655.
doi: 10.3348/kjr.2018.19.4.632 |
| [34] |
曾萧贤, 张文文, 纪立秋, 等.
伴区域淋巴结或合并远处转移的放射性碘难治性分化型甲状腺癌125Ⅰ粒子植入治疗的疗效及安全性[J]. 现代肿瘤医学现代肿瘤医学, 2020, 28(24): 4256-4261.
doi: 10.3969/j.issn.1672-4992.2020.24.009 Zeng XX, Zhang WW, Ji LQ, et al. The efficacy and safety of 125I seeds implantation for the treatment of refractory differentiated thyroid carcinoma with regional lymph node or distant metastasis[J]. J Mod OncolJ Mod Oncol, 2020, 28(24): 4256-4261. doi: 10.3969/j.issn.1672-4992.2020.24.009 |